comparemela.com

Ligand Corporation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer

Sugemalimab Demonstrates Statistically Significant Overall Survival Benefit in Patients with Stage IV Non-Small Cell Lung Cancer
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomMon septDan budwickVince millerCstone pharmaceuticalsWorld health organizationU ligand corporationInternational agency for research on cancerNational medical products administrationEqrx incAmerican cancer societyPivotal phaseLung cancerLigand corporationNew drug application

CStone Pharmaceuticals: CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER

SUZHOU, China, Dec. 21, 2021 /PRNewswire/ CStone Pharmaceuticals (the "Company" or "CStone") is pleased to announce that the National Medical Products Administration ("NMPA") of China has

Jason yangCaicun zhouFrank jiangU ligand corporationPrnewswire cstone pharmaceuticals the companyDrug administrationNational medical products administrationShareholders of the companyDepartment of oncologyOncology trendsPrincipal investigatorShanghai pulmonary hospitalChief medical officerLigand corporationGreater chinaProffered paper oral presentation

CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY® (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Jason yangCaicun zhouFrank jiangSource cstone pharmaceuticalsDrug administrationShareholders of the companyU ligand corporationPrnewswire cstone pharmaceuticals the companyNational medical products administrationDepartment of oncologyOncology trendsPrincipal investigatorShanghai pulmonary hospitalChief medical officerLigand corporationGreater china

CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY® (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER

/PRNewswire/ CStone Pharmaceuticals (the "Company" or "CStone") is pleased to announce that the National Medical Products Administration ("NMPA") of China.

Jason yangCaicun zhouFrank jiangSource cstone pharmaceuticalsDrug administrationShareholders of the companyU ligand corporationPrnewswire cstone pharmaceuticals the companyNational medical products administrationDepartment of oncologyOncology trendsPrincipal investigatorShanghai pulmonary hospitalChief medical officerLigand corporationGreater china

CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY® (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER

/PRNewswire/ CStone Pharmaceuticals (the "Company" or "CStone") is pleased to announce that the National Medical Products Administration ("NMPA") of China.

Jason yangCaicun zhouFrank jiangSource cstone pharmaceuticalsDrug administrationShareholders of the companyU ligand corporationPrnewswire cstone pharmaceuticals the companyNational medical products administrationDepartment of oncologyOncology trendsPrincipal investigatorShanghai pulmonary hospitalChief medical officerLigand corporationGreater china

vimarsana © 2020. All Rights Reserved.